Pages that link to "Q36013325"
Jump to navigation
Jump to search
The following pages link to Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma (Q36013325):
Displaying 50 items.
- Identifying new small molecule anti-invasive compounds for glioma treatment (Q27025151) (← links)
- Hematogenous macrophage depletion reduces the fibrotic scar and increases axonal growth after spinal cord injury (Q27308097) (← links)
- Adaptation to antiangiogenic therapy in neurological tumors (Q28082908) (← links)
- Human iPSC-derived endothelial cell sprouting assay in synthetic hydrogel arrays (Q28397986) (← links)
- Phase II study of sunitinib malate in patients with recurrent high-grade glioma. (Q33392046) (← links)
- Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study (Q33395853) (← links)
- Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma (Q33396181) (← links)
- A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma (Q33402531) (← links)
- Continuous daily sunitinib for recurrent glioblastoma (Q33403947) (← links)
- MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy (Q33616649) (← links)
- Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application (Q33624207) (← links)
- Comparison of three rapamycin dosing schedules in A/J Tsc2 /- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors (Q33711691) (← links)
- Cytosolic Phospholipase A2 and Lysophospholipids in Tumor Angiogenesis (Q34145860) (← links)
- Molecular MRI assessment of vascular endothelial growth factor receptor-2 in rat C6 gliomas (Q34183087) (← links)
- Response-predictive gene expression profiling of glioma progenitor cells in vitro (Q34277599) (← links)
- Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma (Q34334362) (← links)
- Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells (Q34380617) (← links)
- In silico studies on marine actinomycetes as potential inhibitors for Glioblastoma multiforme (Q34951859) (← links)
- The interplay of cyclic stretch and vascular endothelial growth factor in regulating the initial steps for angiogenesis (Q35122448) (← links)
- Sunitinib suppress neuroblastoma growth through degradation of MYCN and inhibition of angiogenesis (Q35156047) (← links)
- A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies (Q35207344) (← links)
- Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer (Q35244205) (← links)
- Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication (Q35506659) (← links)
- Sunitinib Inhibits Cell Proliferation and Alters Steroidogenesis by Down-Regulation of HSD3B2 in Adrenocortical Carcinoma Cells (Q35972295) (← links)
- Sunitinib malate (SU-11248) reduces tumour burden and lung metastasis in an intratibial human xenograft osteosarcoma mouse model. (Q35993110) (← links)
- VB-111: a novel anti-vascular therapeutic for glioblastoma multiforme (Q36096024) (← links)
- A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma (Q36103026) (← links)
- A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development (Q36107975) (← links)
- Glioma revisited: from neurogenesis and cancer stem cells to the epigenetic regulation of the niche (Q36225175) (← links)
- Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors (Q36237312) (← links)
- Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts (Q36335477) (← links)
- Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer (Q36388217) (← links)
- Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy (Q36628029) (← links)
- In Vitro and In Vivo Analysis of RTK Inhibitor Efficacy and Identification of Its Novel Targets in Glioblastomas (Q36723791) (← links)
- Sunitinib enhances neuronal survival in vitro via NF-κB-mediated signaling and expression of cyclooxygenase-2 and inducible nitric oxide synthase (Q37053448) (← links)
- The emerging role of anti-angiogenic therapy for malignant glioma (Q37078957) (← links)
- Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells (Q37147482) (← links)
- Targeted therapies for malignant glioma: progress and potential. (Q37159549) (← links)
- A comparison of PET imaging agents for the assessment of therapy efficacy in a rodent model of glioma (Q37201450) (← links)
- Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model (Q37284263) (← links)
- Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy via Noninvasive PET Molecular Imaging Strategies of Multifactorial Bioparameters (Q37291272) (← links)
- Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain (Q37308322) (← links)
- Molecular profiling in glioblastoma: prelude to personalized treatment (Q37350199) (← links)
- An experimental platform for systemic drug delivery to the retina. (Q37384028) (← links)
- MRI assessment of hemodynamic effects of angiopoietin-2 overexpression in a brain tumor model (Q37395338) (← links)
- Improving the prognosis for patients with glioblastoma: the rationale for targeting Src. (Q37479213) (← links)
- The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma (Q37567174) (← links)
- Quantitative Evaluation of Tumor Early Response to a Vascular-Disrupting Agent with Dynamic PET. (Q37568306) (← links)
- Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma (Q37736273) (← links)
- Gene therapy and virotherapy: novel therapeutic approaches for brain tumors (Q37804933) (← links)